Cadrenal Therapeutics (CVKD) Competitors $16.75 +0.55 (+3.40%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$16.10 -0.65 (-3.88%) As of 04/17/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVKD vs. MCRB, KOD, CHRS, FTLF, EPRX, EDIT, NMRA, TIL, PROC, and FATEShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Seres Therapeutics (MCRB), Kodiak Sciences (KOD), Coherus BioSciences (CHRS), FitLife Brands (FTLF), Eupraxia Pharmaceuticals (EPRX), Editas Medicine (EDIT), Neumora Therapeutics (NMRA), Instil Bio (TIL), Procaps Group (PROC), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Seres Therapeutics Kodiak Sciences Coherus BioSciences FitLife Brands Eupraxia Pharmaceuticals Editas Medicine Neumora Therapeutics Instil Bio Procaps Group Fate Therapeutics Cadrenal Therapeutics (NASDAQ:CVKD) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and earnings. Which has more volatility and risk, CVKD or MCRB? Cadrenal Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.54, indicating that its stock price is 154% more volatile than the S&P 500. Do institutionals and insiders believe in CVKD or MCRB? 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 48.6% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 4.7% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer CVKD or MCRB? Cadrenal Therapeutics currently has a consensus price target of $32.00, indicating a potential upside of 91.04%. Seres Therapeutics has a consensus price target of $4.00, indicating a potential upside of 981.08%. Given Seres Therapeutics' higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer CVKD or MCRB? In the previous week, Seres Therapeutics had 1 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 2 mentions for Seres Therapeutics and 1 mentions for Cadrenal Therapeutics. Seres Therapeutics' average media sentiment score of 0.16 beat Cadrenal Therapeutics' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer CVKD or MCRB? Seres Therapeutics received 525 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 71.37% of users gave Seres Therapeutics an outperform vote. CompanyUnderperformOutperformCadrenal TherapeuticsOutperform Votes6100.00% Underperform VotesNo VotesSeres TherapeuticsOutperform Votes53171.37% Underperform Votes21328.63% Which has preferable earnings and valuation, CVKD or MCRB? Cadrenal Therapeutics has higher earnings, but lower revenue than Seres Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadrenal TherapeuticsN/AN/A-$8.36M-$8.67-1.93Seres Therapeutics$126.33M0.51-$113.72M-$0.23-1.61 Is CVKD or MCRB more profitable? Seres Therapeutics' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cadrenal TherapeuticsN/A -142.95% -118.40% Seres Therapeutics N/A N/A -55.08% SummarySeres Therapeutics beats Cadrenal Therapeutics on 12 of the 16 factors compared between the two stocks. Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.49M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-2.516.8921.8017.80Price / SalesN/A231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book1.895.936.443.98Net Income-$8.36M$142.99M$3.21B$247.73M7 Day Performance11.67%4.42%2.87%1.81%1 Month Performance-13.35%-12.73%-8.63%-6.98%1 Year PerformanceN/A-9.48%11.46%1.37% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics1.9951 of 5 stars$16.75+3.4%$32.00+91.0%N/A$31.49MN/A-2.514News CoverageGap DownMCRBSeres Therapeutics3.0343 of 5 stars$0.66+12.3%$4.00+503.0%-41.0%$115.65M$126.33M-2.88330News CoverageGap UpKODKodiak Sciences3.4934 of 5 stars$2.18flat$9.00+312.8%-21.0%$114.99MN/A-0.6090Short Interest ↑Analyst RevisionNegative NewsCHRSCoherus BioSciences3.618 of 5 stars$0.97+16.6%$5.38+451.5%-47.9%$112.95M$266.96M-12.18330Analyst DowngradeNews CoverageGap DownFTLFFitLife Brands4.2338 of 5 stars$12.07+3.3%$20.50+69.8%-9.9%$111.27M$64.47M14.2820Positive NewsGap UpEPRXEupraxia Pharmaceuticals1.7821 of 5 stars$3.10+2.3%$10.50+238.7%+25.4%$111.13MN/A-4.3129EDITEditas Medicine4.0135 of 5 stars$1.32+1.5%$6.83+417.7%-77.1%$110.50M$32.31M-0.52230Analyst RevisionNews CoveragePositive NewsGap UpNMRANeumora Therapeutics3.1678 of 5 stars$0.67-1.8%$9.29+1,286.3%-93.8%$110.44MN/A-0.36108TILInstil Bio2.0875 of 5 stars$16.80+11.8%$114.00+578.6%+45.9%$109.64MN/A-1.45410PROCProcaps GroupN/A$0.95-40.3%N/A-64.6%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeFATEFate Therapeutics3.4938 of 5 stars$0.92-12.8%$5.43+487.3%-78.9%$105.93M$13.63M-0.56550News CoverageGap Down Related Companies and Tools Related Companies MCRB Competitors KOD Competitors CHRS Competitors FTLF Competitors EPRX Competitors EDIT Competitors NMRA Competitors TIL Competitors PROC Competitors FATE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVKD) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CVKD Stock Free CVKD Stock Alerts